盐酸埃克替尼片联合吉西他滨+卡铂对非小细胞肺癌患者细胞免疫功能及血清肿瘤标志物水平的影响  

Effects of Ecatinib hydrochloride tablets combination with gemcitabine and carboplatin on cellular immune function and serum tumor marker levels in patients with non-small cell lung cancer

作　　者：张凤鸣 赵旭林[1] 陆娟[1] Zhang Feng-ming;Zhao Xu-lin;Lu Juan(Department of Oncology,Nanyang First People's Hospital,Nanyang 473000,Henan,China)

机构地区：[1]南阳市第一人民医院肿瘤内一科,河南南阳473000

出　　处：《四川生理科学杂志》2025年第3期622-625,共4页

摘　　要：目的:研究盐酸埃克替尼片联合吉西他滨^(+)卡铂治疗非小细胞肺癌(Non-small cell lung cancer,NSCLC)患者的效果。方法:回顾性分析2021年12月至2023年10月我院收治的NSCLC患者89例,以不同治疗方案分为两组。对照组(n=46)采用吉西他滨1 g^(+)卡铂5 mg静脉滴注治疗,观察组(n=43)基于对照组增加盐酸埃克替尼片125 mg口服治疗,两组持续治疗4个周期。比较两组临床疗效,于治疗前后采用流式细胞仪检测细胞免疫功能(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)),采用化学发光法检测并比较两组的肿瘤标志物水平,包括糖类抗原199(Carbohydrate antigen 199,CA199)、癌抗原125(Cancer antigen 125,CA125)、细胞角质素片段抗原21-1(Cellular keratin fragment antigen 21-1,CYFRA21-1)、癌胚抗原(Carcinoembryonic antigen,CEA),采用酶联免疫吸附法检测并比较两组的转化生长因子β1(Transforming growth factor-β1,TGF-β1)、血管内皮生长因子(Vascular endothelial growth factor,VEGF)水平,并分析比较两组治疗期间肾毒性、骨髓抑制、白细胞减少发生率。结果:观察组临床总有效率高于对照组(P<0.05),且两组肾毒性、骨髓抑制、白细胞减少发生率比较,无明显差异(P>0.05);治疗后观察组CA199、CA125、CYFRA21-1、CEA、TGF-β1、VEGF低于对照组(P<0.05);治疗后观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于对照组(P<0.05)。结论:盐酸埃克替尼片联合吉西他滨^(+)卡铂治疗可增强NSCLC患者免疫功能,抑制机体肿瘤细胞生长,控制病情进展。Objective:To study the effect of Icotinib Hydrochloride Tablets combined with gemcitabine^(+)carboplatin in patients with non-small cell lung cancer(NSCLC).Methods:A retrospective analysis was conducted on 89 NSCLC patients admitted to our hospital from December 2021 to October 2023,who were divided into two groups based on different treatment plans.The control group(n=46)was treated with intravenous infusion of gemcitabine 1 g^(+)carboplatin 5 mg,and the observation group(n=43)was treated with oral administration of Icotinib Hydrochloride Tablets 125 mg based on the control group,with both groups receiving continuous treatment for 4 cycles.The clinical efficacy of the two groups was compared,and the cellular immune function(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))was detected by flow cytometry before and after treatment.The levels of tumor markers,including carbohydrate antigen 199(CA199),cancer antigen 125(CA125),cellular keratin fragment antigen 21-1(CYFRA21-1),and carcinoembryonic antigen(CEA)were detected by the chemiluminescence method.Moreover,the levels of transforming growth factor-β1(TGF-β1)and vascular endothelial growth factor(VEGF-β1)were measured by enzyme-linked immunosorbent assay.The incidences of nephrotoxicity,bone marrow suppression,and leukopenia were analyzed.Results:The total clinical effective rate in the observation group was higher than that in the control group(P<0.05),and there was no significant difference in the incidence of nephrotoxicity,bone marrow suppression,and leukopenia between the two groups(P>0.05).After treatment,the levels of CA199,CA125,CYFRA21-1,CEA,TGF-β1,and VEGF in the observation group were lower than those in the control group(P<0.05).After treatment,the CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)levels in the observation group were higher than in the control group(P<0.05).Conclusion:The combination of Icotinib Hydrochloride Tablets and gemcitabine^(+)carboplatin can enhance the immune function of NSCLC patients,inhibit the growth of tumor cells in the body,and control the

关 键 词：盐酸埃克替尼片 吉西他滨 卡铂 非小细胞肺癌 

分 类 号：R73[医药卫生—肿瘤]